Rosa Rademakers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4334488/publications.pdf

Version: 2024-02-01

		4641	3257
279	39,326	85	185
papers	citations	h-index	g-index

298	298	298	25532
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cortical and subcortical pathological burden and neuronal loss in an autopsy series of FTLD-TDP-type C. Brain, 2022, 145, 1069-1078.	3.7	12
2	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
3	Revealing the Mutational Spectrum in Southern Africans With Amyotrophic Lateral Sclerosis. Neurology: Genetics, 2022, 8, e654.	0.9	10
4	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
5	Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell, 2022, 185, 1346-1355.e15.	13.5	70
6	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6
7	Underlying genetic variation in familial frontotemporal dementia: sequencing of 198 patients. Neurobiology of Aging, 2021, 97, 148.e9-148.e16.	1.5	17
8	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
9	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533.	2.8	21
10	Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology. Advances in Experimental Medicine and Biology, 2021, 1281, 219-242.	0.8	11
11	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 17-28.	0.7	5
12	Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease. Neurology, 2021, 96, e1755-e1760.	1.5	1
13	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathologica, 2021, 141, 667-680.	3.9	5
14	Loss of Tmem106b leads to cerebellum Purkinje cell death and motor deficits. Brain Pathology, 2021, 31, e12945.	2.1	8
15	Impact of variant-level batch effects on identification of genetic risk factors in large sequencing studies. PLoS ONE, 2021, 16, e0249305.	1.1	5
16	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
17	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
18	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10

#	Article	IF	Citations
19	Old age genetically confirmed frontotemporal lobar degeneration with TDPâ€43 has limbic predominant TDPâ€43 deposition. Neuropathology and Applied Neurobiology, 2021, 47, 1050-1059.	1.8	10
20	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	5.8	34
21	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	4.5	46
22	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
23	FDG-PET in presymptomatic C9orf72 mutation carriers. NeuroImage: Clinical, 2021, 31, 102687.	1.4	16
24	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
25	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	3.7	7
26	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	3.3	13
27	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	9.4	223
28	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
29	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
30	GBA variation and susceptibility to multiple system atrophy. Parkinsonism and Related Disorders, 2020, 77, 64-69.	1.1	12
31	Sensitivityâ€“Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	2.8	32
32	Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy. Acta Neuropathologica Communications, 2020, 8, 72.	2.4	42
33	Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. Brain, 2020, 143, 1905-1919.	3.7	44
34	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
35	Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Molecular Neurodegeneration, 2020, 15, 7.	4.4	34
36	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	3.9	117

#	Article	IF	Citations
37	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
38	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology, 2020, 95, e59-e69.	1.5	119
39	Loss of Tmem106b exacerbates <scp>FTLD</scp> pathologies and causes motor deficits in progranulinâ€deficient mice. EMBO Reports, 2020, 21, e50197.	2.0	35
40	EIF2AK3 variants in Dutch patients with Alzheimer's disease. Neurobiology of Aging, 2019, 73, 229.e11-229.e18.	1.5	25
41	FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology. Journal of Neuropathology and Experimental Neurology, 2019, 78, 844-853.	0.9	9
42	Clinicopathologic correlations in a family with aTBK1mutation presenting as primary progressive aphasia and primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 568-575.	1.1	24
43	Coexistence of Progressive Supranuclear Palsy With Pontocerebellar Atrophy and Myotonic Dystrophy Type 1. Journal of Neuropathology and Experimental Neurology, 2019, 78, 756-762.	0.9	3
44	C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. Acta Neuropathologica Communications, 2019, 7, 100.	2.4	11
45	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
46	Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. Annals of Clinical and Translational Neurology, 2019, 6, 1782-1796.	1.7	20
47	Enhanced phosphorylation of T153 in soluble tau is a defining biochemical feature of the A152T tau risk variant. Acta Neuropathologica Communications, 2019, 7, 10.	2.4	3
48	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
49	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
50	Systematic analysis of dark and camouflaged genes reveals disease-relevant genes hiding in plain sight. Genome Biology, 2019, 20, 97.	3.8	122
51	Revisiting the utility of TDP-43 immunoreactive (TDP-43-ir) pathology to classify FTLD-TDP subtypes. Acta Neuropathologica, 2019, 138, 167-169.	3.9	10
52	Gyrification abnormalities in presymptomatic c9orf72 expansion carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1005-1010.	0.9	24
53	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	3.7	873
54	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	4.5	39

#	Article	IF	Citations
55	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. NeuroImage: Clinical, 2019, 22, 101751.	1.4	30
56	CSF1R mutation presenting as dementia with Lewy bodies. Neurocase, 2019, 25, 17-20.	0.2	9
57	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
58	Ossified blood vessels in primary familial brain calcification elicit a neurotoxic astrocyte response. Brain, 2019, 142, 885-902.	3.7	50
59	Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science, 2019, 363, .	6.0	181
60	Preferential Disruption of Auditory Word Representations in Primary Progressive Aphasia With the Neuropathology of FTLD-TDP Type A. Cognitive and Behavioral Neurology, 2019, 32, 46-53.	0.5	14
61	Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nature Neuroscience, 2019, 22, 1966-1974.	7.1	101
62	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
63	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica, 2019, 137, 227-238.	3.9	65
64	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
65	Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Annals of Clinical and Translational Neurology, 2018, 5, 583-597.	1.7	48
66	Repeat expansions in myoclonic epilepsy. Nature Genetics, 2018, 50, 477-478.	9.4	0
67	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
68	Mitotic defects lead to neuronal aneuploidy and apoptosis in frontotemporal lobar degeneration caused by MAPT mutations. Molecular Biology of the Cell, 2018, 29, 575-586.	0.9	36
69	Unaffected mosaic C9orf72 case. Neurology, 2018, 90, e323-e331.	1.5	33
70	Relationships between lewy and tau pathologies in 375 consecutive nonâ€Alzheimer's olfactory bulbs. Movement Disorders, 2018, 33, 333-334.	2.2	1
71	TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nature Neuroscience, 2018, 21, 228-239.	7.1	404
72	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. Alzheimer's Research and Therapy, 2018, 10, 2.	3.0	25

#	Article	IF	Citations
73	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
74	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
75	Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 469-471.	1.1	15
76	Combined Pathologies in FTLD-TDP Types A and C. Journal of Neuropathology and Experimental Neurology, 2018, 77, 405-412.	0.9	8
77	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
78	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
79	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
80	APOE Îµ2 is associated with increased tau pathology in primary tauopathy. Nature Communications, 2018, 9, 4388.	5.8	100
81	Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. NeuroImage: Clinical, 2018, 18, 591-598.	1.4	26
82	Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nature Medicine, 2018, 24, 1136-1142.	15.2	241
83	Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. Acta Neuropathologica Communications, 2018, 6, 42.	2.4	20
84	Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Molecular Neurodegeneration, 2018, 13, 37.	4.4	54
85	Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathologica Communications, 2018, 6, 63.	2.4	79
86	Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. Molecular Neurodegeneration, 2018, 13, 32.	4.4	25
87	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	1.7	39
88	TMEM106B haplotypes have distinct gene expression patterns in aged brain. Molecular Neurodegeneration, 2018, 13, 35.	4.4	30
89	Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathologica Communications, 2018, 6, 55.	2.4	24
90	Identification of missing variants by combining multiple analytic pipelines. BMC Bioinformatics, 2018, 19, 139.	1.2	10

#	Article	IF	Citations
91	Long-read sequencing across the C9orf72 â€˜GGGGCCâ€™ repeat expansion: implications for clinical use and genetic discovery efforts in human disease. Molecular Neurodegeneration, 2018, 13, 46.	4.4	111
92	Three VCP Mutations in Patients with Frontotemporal Dementia. Journal of Alzheimer's Disease, 2018, 65, 1139-1146.	1.2	19
93	ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiology of Aging, 2017, 51, 178.e1-178.e9.	1.5	86
94	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	3.9	90
95	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55
96	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
97	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	179
98	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Movement Disorders, 2017, 32, 246-255.	2.2	46
99	Dementia Researchâ€”A Roadmap for the Next Decade. JAMA Neurology, 2017, 74, 141.	4.5	3
100	Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. NeuroImage: Clinical, 2017, 14, 286-297.	1.4	129
101	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Movement Disorders, 2017, 32, 1772-1779.	2.2	46
102	Disease and Region Specificity of Granulin Immunopositivities in Alzheimer Disease and Frontotemporal Lobar Degeneration. Journal of Neuropathology and Experimental Neurology, 2017, 76, 957-968.	0.9	22
103	Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency. Cell Reports, 2017, 20, 2565-2574.	2.9	98
104	DCTN1 variation in pathologically-confirmed PSP and CBD tauopathy. Parkinsonism and Related Disorders, 2017, 44, 151-153.	1.1	3
105	Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Research, 2017, 27, 1895-1903.	2.4	277
106	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	3.8	493
107	Conserved DNA methylation combined with differential frontal cortex and cerebellar expression distinguishes C9orf72-associated and sporadic ALS, and implicates SERPINA1 in disease. Acta Neuropathologica, 2017, 134, 715-728.	3.9	40
108	Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Human Molecular Genetics, 2017, 26, 3421-3431.	1.4	101

#	Article	IF	Citations
109	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
110	<scp>S</scp>tudy of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Movement Disorders, 2017, 32, 115-123.	2.2	48
111	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
112	TMEM106B and myelination: rare leukodystrophy families reveal unexpected connections. Brain, 2017, 140, 3069-3080.	3.7	3
113	Brain calcifications and PCDH12 variants. Neurology: Genetics, 2017, 3, e166.	0.9	15
114	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	0.9	2
115	Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathologica Communications, 2017, 5, 96.	2.4	38
116	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSPâ€. Movement Disorders, 2016, 31, 653-662.	2.2	60
117	Tremor in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 27, 93-97.	1.1	17
118	Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell, 2016, 165, 921-935.	13.5	558
119	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	4.4	34
120	Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals. Experimental Gerontology, 2016, 84, 96-100.	1.2	14
121	Primary familial brain calcification in the â€˜IBGC2â€™ kindred: All linkage roads lead toSLC20A2. Movement Disorders, 2016, 31, 1901-1904.	2.2	16
122	Modifiers of LRRK2 parkinsonism: new therapeutic targets. Lancet Neurology, The, 2016, 15, 1200-1201.	4.9	2
123	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
124	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
125	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
126	Genetics of <scp>FTLD</scp>: overview and what else we can expect from genetic studies. Journal of Neurochemistry, 2016, 138, 32-53.	2.1	118

#	Article	IF	Citations
127	What we know about TMEM106B in neurodegeneration. Acta Neuropathologica, 2016, 132, 639-651.	3.9	83
128	Prosaposin is a regulator of progranulin levels and oligomerization. Nature Communications, 2016, 7, 11992.	5.8	68
129	Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e301.	3.1	78
130	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
131	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	9.4	218
132	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	5.8	174
133	Genetic Disorders with Tau Pathology: A Review of the Literature and Report of Two Patients with Tauopathy and Positive Family Histories. Neurodegenerative Diseases, 2016, 16, 12-21.	0.8	35
134	C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nature Neuroscience, 2016, 19, 668-677.	7.1	268
135	Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome. Neurology, 2016, 86, 1164-1166.	1.5	8
136	C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. Experimental Neurology, 2016, 277, 171-177.	2.0	21
137	Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory Dysfunction. PLoS ONE, 2016, 11, e0165112.	1.1	10
138	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. American Journal of Neurodegenerative Disease, 2016, 5, 94-101.	0.1	4
139	Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Molecular Neurodegeneration, 2015, 10, 46.	4.4	58
140	Jump from Pre-mutation to Pathologic Expansion in C9orf72. American Journal of Human Genetics, 2015, 96, 962-970.	2.6	50
141	A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathologica, 2015, 130, 199-214.	3.9	38
142	Dominant Frontotemporal Dementia Mutations in 140 Cases of Primary Progressive Aphasia and Speech Apraxia. Dementia and Geriatric Cognitive Disorders, 2015, 39, 281-286.	0.7	32
143	TREM2 in CNS homeostasis and neurodegenerative disease. Molecular Neurodegeneration, 2015, 10, 43.	4.4	115
144	A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1042-1052.	0.9	27

#	Article	IF	Citations
145	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathologica, 2015, 130, 877-889.	3.9	235
146	Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. Parkinsonism and Related Disorders, 2015, 21, 101-105.	1.1	42
147	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53.	0.8	49
148	Clinical presentation of a patient with SLC20A2 and THAP1 deletions: Differential diagnosis of oromandibular dystonia. Parkinsonism and Related Disorders, 2015, 21, 329-331.	1.1	5
149	Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Annals of the New York Academy of Sciences, 2015, 1338, 71-93.	1.8	97
150	A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration. Acta Neuropathologica, 2015, 130, 145-157.	3.9	24
151	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Experimental Neurology, 2015, 271, 241-250.	2.0	25
152	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
153	Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nature Neuroscience, 2015, 18, 1175-1182.	7.1	330
154	C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science, 2015, 348, 1151-1154.	6.0	332
155	PRKAR1B mutations are a rare cause of FUS negative neuronal intermediate filament inclusion disease. Brain, 2015, 138, e357-e357.	3.7	9
156	Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathologica, 2015, 130, 77-92.	3.9	267
157	Pathologic Staging of White Matter Lesions in Adult-Onset Leukoencephalopathy/Leukodystrophy With Axonal Spheroids. Journal of Neuropathology and Experimental Neurology, 2015, 74, 233-240.	0.9	16
158	C9orf72 repeats compromise nucleocytoplasmic transport. Nature Reviews Neurology, 2015, 11, 670-672.	4.9	12
159	Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. European Journal of Neurology, 2015, 22, 328-333.	1.7	40
160	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
161	A Point Mutation in PDGFRB Causes Autosomal-Dominant Penttinen Syndrome. American Journal of Human Genetics, 2015, 97, 465-474.	2.6	64
162	Diffuse leukoencephalopathy with spheroids presenting as primary progressive aphasia. Neurology, 2015, 85, 652-653.	1.5	12

#	Article	IF	Citations
163	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
164	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
165	Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). Journal of Biological Chemistry, 2015, 290, 26043-26050.	1.6	395
166	Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathologica, 2015, 129, 53-64.	3.9	67
167	Adult polyglucosan body disease with <scp>GBE1</scp> haploinsufficiency and concomitant frontotemporal lobar degeneration. Neuropathology and Applied Neurobiology, 2014, 40, 778-782.	1.8	7
168	The GGGGCC Repeat Expansion inC9ORF72in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome. Neurocase, 2014, 20, 110-120.	0.2	15
169	Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain, 2014, 137, 3047-3060.	3.7	140
170	Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathologica, 2014, 128, 505-524.	3.9	284
171	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Molecular Neurodegeneration, 2014, 9, 38.	4.4	63
172	Analysis of COQ2gene in multiple system atrophy. Molecular Neurodegeneration, 2014, 9, 44.	4.4	40
173	A NovelGRNMutation (GRNc.708+6_+9delTGAG) in Frontotemporal Lobar Degeneration With TDP-43â€“Positive Inclusions. Journal of Neuropathology and Experimental Neurology, 2014, 73, 467-473.	0.9	7
174	Early Neuropsychological Characteristics of Progranulin Mutation Carriers. Journal of the International Neuropsychological Society, 2014, 20, 694-703.	1.2	21
175	ExpandedC9ORF72Hexanucleotide Repeat in Depressive Pseudodementia. JAMA Neurology, 2014, 71, 775.	4.5	28
176	The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 84-92.	0.4	55
177	Progranulin-associated PiB-negative logopenic primary progressive aphasia. Journal of Neurology, 2014, 261, 604-614.	1.8	69
178	Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathologica, 2014, 127, 271-282.	3.9	66
179	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 2014, 127, 397-406.	3.9	133
180	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics, 2014, 15, 23-30.	0.7	56

#	Article	IF	Citations
181	Genetic Screening and Functional Characterization ofPDGFRBMutations Associated with Basal Ganglia Calcification of Unknown Etiology. Human Mutation, 2014, 35, 964-971.	1.1	45
182	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424.	1.5	118
183	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
184	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	1.1	6
185	Excess of Rare Damaging TUBA4A Variants Suggests Cytoskeletal Defects in ALS. Neuron, 2014, 84, 241-243.	3.8	18
186	Progranulin protein levels are differently regulated in plasma and CSF. Neurology, 2014, 82, 1871-1878.	1.5	70
187	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron, 2014, 83, 1043-1050.	3.8	289
188	Identical twins with the C9orf72 repeat expansion are discordant for ALS. Neurology, 2014, 83, 1476-1478.	1.5	40
189	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
190	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimerâ€™s disease. Brain, 2014, 137, 1533-1549.	3.7	100
191	Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathologica, 2014, 128, 411-421.	3.9	119
192	A nonsense mutation in PRNP associated with clinical Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2656.e13-2656.e16.	1.5	26
193	PL-04-01: UPDATE ON C9ORF72 RESEARCH IN FTLD AND ALS. , 2014, 10, P248-P248.		0
194	Frontotemporal lobar degeneration with TDPâ€43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation. Neuropathology, 2013, 33, 122-133.	0.7	45
195	TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinsonâ€™s disease. Molecular Neurodegeneration, 2013, 8, 19.	4.4	323
196	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurology, The, 2013, 12, 978-988.	4.9	232
197	TREM2 Variants in Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 117-127.	13.9	2,385
198	Analysis of the C9orf72 repeat in Parkinson's disease, essential tremor and restless legs syndrome. Parkinsonism and Related Disorders, 2013, 19, 198-201.	1.1	37

#	Article	IF	Citations
199	Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathologica, 2013, 125, 289-302.	3.9	87
200	Novel causal genes and disease modifiers. Nature Reviews Neurology, 2013, 9, 63-64.	4.9	28
201	Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS. Neuron, 2013, 77, 639-646.	3.8	962
202	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism and Related Disorders, 2013, 19, 869-877.	1.1	119
203	Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of Aging, 2013, 34, 2235.e11-2235.e13.	1.5	13
204	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature, 2013, 495, 467-473.	13.7	1,249
205	Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathologica, 2013, 126, 829-844.	3.9	506
206	Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathologica, 2013, 126, 895-905.	3.9	263
207	Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathologica, 2013, 126, 545-554.	3.9	30
208	An adult-onset leukoencephalopathy with axonal spheroids and pigmented glia accompanied by brain calcifications. Journal of Neurology, 2013, 260, 2665-2668.	1.8	22
209	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.5	84
210	Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. Neurology, 2013, 80, 2076-2078.	1.5	31
211	CSF1R mutations link POLD and HDLS as a single disease entity. Neurology, 2013, 80, 1033-1040.	1.5	136
212	TDP-43 frontotemporal lobar degeneration and autoimmune disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 956-962.	0.9	137
213	Profilin-1 mutations are rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 463-469.	1.1	25
214	<scp>TMEM</scp>106B p.T185S regulates <scp>TMEM</scp>106B protein levels: implications for frontotemporal dementia. Journal of Neurochemistry, 2013, 126, 781-791.	2.1	87
215	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain, 2012, 135, 794-806.	3.7	355
216	How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia. Current Opinion in Neurology, 2012, 25, 689-700.	1.8	169

#	Article	IF	Citations
217	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics, 2012, 21, 3500-3512.	1.4	198
218	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain, 2012, 135, 765-783.	3.7	322
219	Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nature Genetics, 2012, 44, 200-205.	9.4	428
220	Frontotemporal dementia due to C9ORF72 mutations. Neurology, 2012, 79, 1002-1011.	1.5	183
221	TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology, 2012, 79, 717-718.	1.5	81
222	TARDBP Mutation Analysis in TDP-43 Proteinopathies and Deciphering the Toxicity of Mutant TDP-43. Journal of Alzheimer's Disease, 2012, 33, S35-S45.	1.2	43
223	Progranulin axis and recent developments in frontotemporal lobar degeneration. Alzheimer's Research and Therapy, 2012, 4, 4.	3.0	20
224	Pathogenicity of exonic indels in fused in sarcoma in amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 424.e23-424.e24.	1.5	5
225	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	1.5	115
226	Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiology of Aging, 2012, 33, 2950.e5-2950.e7.	1.5	83
227	Advances in understanding the molecular basis of frontotemporal dementia. Nature Reviews Neurology, 2012, 8, 423-434.	4.9	353
228	Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Molecular Neurodegeneration, 2012, 7, 53.	4.4	61
229	Progranulin regulates neuronal outgrowth independent of Sortilin. Molecular Neurodegeneration, 2012, 7, 33.	4.4	129
230	MRI characteristics and scoring in HDLS due to CSF1R gene mutations. Neurology, 2012, 79, 566-574.	1.5	153
231	Angiogenin variation and Parkinson disease. Annals of Neurology, 2012, 71, 725-727.	2.8	23
232	C9orf72 repeat expansions in patients with ALS and FTD. Lancet Neurology, The, 2012, 11, 297-298.	4.9	46
233	C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. American Journal of Neurodegenerative Disease, 2012, 1, 107-18.	0.1	32
234	rs5848 polymorphism and serum progranulin level. Journal of the Neurological Sciences, 2011, 300, 28-32.	0.3	77

#	Article	IF	Citations
235	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	9.4	502
236	Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nature Reviews Neurology, 2011, 7, 263-272.	4.9	270
237	Ataxin-2 repeat-length variation and neurodegeneration. Human Molecular Genetics, 2011, 20, 3207-3212.	1.4	147
238	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	3.8	4,176
239	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathologica, 2011, 122, 673-690.	3.9	277
240	Human Genetics as a Tool to Identify Progranulin Regulators. Journal of Molecular Neuroscience, 2011, 45, 532-537.	1.1	4
241	Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. BMC Genomics, 2011, 12, 527.	1.2	48
242	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.9	108
243	FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain, 2011, 134, 2595-2609.	3.7	247
244	Hippocampal Sclerosis in the Elderly. Alzheimer Disease and Associated Disorders, 2011, 25, 364-368.	0.6	78
245	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain, 2011, 134, 3264-3275.	3.7	119
246	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 196-203.	0.9	170
247	Alzheimer Diseaseâ€"like Phenotype Associated With the c.154delA Mutation in Progranulin. Archives of Neurology, 2010, 67, 171-7.	4.9	59
248	Genome-wide Screen Identifies rs646776 near Sortilin as a Regulator of Progranulin Levels in Human Plasma. American Journal of Human Genetics, 2010, 87, 890-897.	2.6	130
249	Sporadic corticobasal syndrome due to FTLD-TDP. Acta Neuropathologica, 2010, 119, 365-374.	3.9	59
250	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	3.9	222
251	TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurology, The, 2010, 9, 995-1007.	4.9	816
252	De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Human Mutation, 2010, 31, E1377-E1389.	1.1	141

#	Article	IF	Citations
253	Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle and Nerve, 2010, 42, 170-176.	1.0	101
254	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
255	Common Variant in <i>GRN</i> Is a Genetic Risk Factor for Hippocampal Sclerosis in the Elderly. Neurodegenerative Diseases, 2010, 7, 170-174.	0.8	82
256	Frontotemporal Dementia. Blue Books of Neurology, 2010, 34, 397-416.	0.1	0
257	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain, 2009, 132, 583-591.	3.7	344
258	A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain, 2009, 132, 2922-2931.	3.7	628
259	TARDBP 3â€²-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathologica, 2009, 118, 633-645.	3.9	139
260	Unilateral neglect in a patient diagnosed with frontotemporal dementia and parkinsonism linked to chromosome 17. Acta Neuropsychiatrica, 2009, 21, 209-210.	1.0	4
261	Recent insights into the molecular genetics of dementia. Trends in Neurosciences, 2009, 32, 451-461.	4.2	51
262	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. Neurobiology of Aging, 2009, 30, 656-665.	1.5	33
263	Progranulin gene mutation with an unusual clinical and neuropathologic presentation. Movement Disorders, 2008, 23, 1168-1173.	2.2	36
264	Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis. PLoS Genetics, 2008, 4, e1000193.	1.5	393
265	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	1.4	271
266	The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Current Opinion in Neurology, 2008, 21, 693-700.	1.8	150
267	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 142-151.	0.9	184
268	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477Câ†'T (Arg493X) mutation: an international initiative. Lancet Neurology, The, 2007, 6, 857-868.	4.9	199
269	The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics, 2007, 8, 237-248.	0.7	76
270	The genetics of frontotemporal lobar degeneration. Current Neurology and Neuroscience Reports, 2007, 7, 434-442.	2.0	43

#	Article	IF	Citations
271	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442, 916-919.	13.7	1,816
272	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 2006, 442, 920-924.	13.7	1,386
273	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain, 2006, 129, 841-852.	3.7	88
274	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain, 2006, 129, 3081-3090.	3.7	291
275	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Human Molecular Genetics, 2006, 15, 2988-3001.	1.4	529
276	Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. Human Molecular Genetics, 2005, 14, 1753-1762.	1.4	82
277	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Human Molecular Genetics, 2005, 14, 3281-3292.	1.4	156
278	Linkage and Association Studies Identify a Novel Locus for Alzheimer Disease at 7q36 in a Dutch Population-Based Sample. American Journal of Human Genetics, 2005, 77, 643-652.	2.6	48
279	Genetics of Early-Onset Alzheimer Dementia. Scientific World Journal, The, 2003, 3, 497-519.	0.8	40